Bivatuzumab

DB06550InvestigationalProtein Based Therapies

Bivatuzumab (previously BIWA 4) is a humanized monoclonal antibody against CD44 v6.

Protein structure of Bivatuzumab
Mechanism
Curator reviewed
Primary indication
Investigated for use/treatment in cancer/tumors (unspecified) and head and neck cancer.Curator reviewed
Code names
BIWA 4

Resolves to

Compound
UNII0A0Z1IJN86
Targets
P16070CD44

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
382Drug interactionsStructured to mechanism, not free text
Sign in
2Clinical trialsPhase, status and sponsor resolved per trial
Sign in
4+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Bivatuzumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In